newsfilter
← Latest News
GlobeNewswire·

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations – – Presented positive data at ATS 2025 and EAACI 2025 supporting the potential of